Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Profile Name | PALB2 Y551* PALB2 S859* |
| Gene Variant Detail | |
| Relevant Treatment Approaches |
| Molecular Profile | Indication/Tumor Type | Response Type | Relevant Treatment Approaches | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|---|
| PALB2 Y551* PALB2 S859* | Her2-receptor negative breast cancer | predicted - sensitive | Olaparib | Case Reports/Case Series | Actionable | In a clinical case study, a patient with metastatic hormone receptor (ESR1/PGR)-positive, ERBB2 (HER2)-negative breast cancer harboring PALB2 Y551* and S859* who progressed on prior therapies achieved a partial response to Lynparza (olaparib) treatment after 3 months and a 70% decrease in tumor burden at 6 months (PMID: 32194151). | 32194151 |